Skip to main content
. 2018 Sep 20;19(10):2846. doi: 10.3390/ijms19102846

Figure 6.

Figure 6

CMS-2 activates melanogenesis in melanoma and melanocyte cell line. Cell melanogenesis was evaluated by measuring the amount of melanin and tyrosinase activity after 24 h of CMS-2 treatment (1–10 μg/mL): melanin content in B16-F10 (A) and Melan-a (B); and tyrosinase activity in B16-F10 (C) and Melan-a (D). * p < 0.05 and ** p < 0.01, analysis of variance, Newman–Keuls post-test.